| |
 Barbara
S. Schilberg, Managing Director and Chief Executive
Officer
"We have a tremendous opportunity to galvanize economic
growth in southeastern Pennsylvania by building on our depth
and breadth in the life sciences, particularly in biopharmaceuticals
and medical devices. The funding from the Commonwealth allows
BioAdvance to provide critical capital and other support to
help entrepreneurs move science from the laboratory into successful
businesses."
Barbara has over 17 years of experience in the biopharmaceutical
industry. As a senior executive of four emerging life sciences
companies, she brings broad experience in the key elements
needed to build successful companies, including public and
private financings, intellectual property protection, corporate
partnering arrangements and the management of research programs.
Before joining the industry, she specialized in representing
biopharmaceutical companies and research institutions in the
commercialization of technology.
While a partner in the Philadelphia office of Morgan, Lewis
& Bockius, she developed novel strategies for the licensing
and commercialization of life sciences technology on behalf
of biopharmaceutical companies such as Cephalon, Inc. and
non-profit research institutions such as the University of
Pennsylvania, The Wistar Institute and Thomas Jefferson University.
Her practice supported a wide range of industry activities,
including venture capital financings, IPOs and other public
offerings, marketing, co-development and joint-venture arrangements,
sponsored research, and technology transfer.
She was recruited in 1994 to Cephalon in West Chester, PA
where she served as Senior Vice President and General Counsel,
and as a member of the executive committee. In addition to
those responsibilities, she led a multi-disciplinary team
charged with completing Phase III clinical trials and preparing
a new drug application for PROVIGIL® (modafinil), which
was approved by the FDA in December 1999. She joined Incara
Pharmaceuticals in 1998 as Executive Vice President and General
Counsel. As part of her responsibilities she managed a research
operation in Princeton, NJ engaged in discovering new antibacterial
therapeutics, and continued in that capacity after the operation's
acquisition by Advanced Medicine in 2000. Barbara was most
recently employed as Vice President and General Counsel at
Locus Discovery, Inc., an emerging pharmaceutical company
in Blue Bell, PA engaged in computational drug design.
Barbara received her J.D. from the University of Virginia
and clerked with the Honorable Edward R. Becker, now Senior
Judge of the U.S. Court of Appeals for the Third Circuit.
Contact: bschilberg@bioadvance.com
 Gary
J. Kurtzman, M.D.,
Managing Director & Chief Operating Officer
"Having been involved with the biotech industry
elsewhere, I understand that this region has incomparable
biomedical research institutions, talent and resources. I
am excited about the central role BioAdvance will play in
moving technology from the laboratory and into the next generation
of life sciences companies."
Gary has spent over 20 years in the life sciences, including
experience in medicine, academic and government-sponsored
research and as an executive with several biotechnology companies.
Along the way, he has participated in many ¡°start-up¡±
activities including creating corporate strategy and infrastructure,
private and public fundraising, corporate collaboration, technology
assessment and licensing, intellectual property and M&A.
Following research training at the National Institutes of
Health and Stanford University in virology and hematology,
Gary joined Gilead Sciences, then a pre-IPO California biotech
company, in 1991, as head of the virology research and preclinical
development group. In 1993, he was recruited to Avigen, an
early stage gene therapy company in the San Francisco Bay
Area as head of R&D, and in 1998 joined Genovo, a Philadelphia
area gene therapy start-up, as Chief Operating Officer. In
these roles he worked closely with investigators at several
academic centers including the Children¡¯s Hospital of
Philadelphia and the University of Pennsylvania to advance
research from the laboratory into commercial application.
After leaving Genovo in early 2001 following its acquisition
by Targeted Genetics Corporation of Seattle, WA, Dr. Kurtzman
was Chief Executive Officer of Pluvita, a venture-backed company
in Bethesda, MD identifying cutting-edge science to accelerate
the drug discovery and development process.
Gary received his undergraduate degree in biological sciences
from Stanford University. He received his M.D. degree and
medical training at Washington University in St. Louis and
Stanford University and is a board certified internist with
a hematology subspecialty. He has authored more than 40 research
articles, book chapters and reviews and is the inventor on
thirteen issued U.S. patents.
Contact: gkurtzman@bioadvance.com
|
